Roberto Pierini, PhD

CHIESI GLOBAL RARE DISEASES, Paris, France
Paris, France

Disclosure information not submitted.

Presentation(s):

• SAT-658 - A 36-Month, Multicenter, Open Label Phase 4 Study to Evaluate the Immunogenicity of Daily Metreleptin Treatment in Patients with Generalized Lipodystrophy

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT